INCY News and Press, Incyte Corporation From 11/19/20

Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19 - ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment - Authorization enables use of baricitinib in combination with...

Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory di...

Incyte (Nasdaq:INCY) today announced that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually from November 11-14, 2020. “We are excited to join the oncology community at th...

HQH offers investors a quarterly distribution based on 2% of the NAV. Due to the fund's significant discount, the yield shareholders actually receive is even more attractive. The fund has also been a great performer due to the pandemic. For further details see: HQH: Deep...

Image source: The Motley Fool. Incyte Corp (NASDAQ: INCY) Q3 2020 Earnings Call Nov 5, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Incyte Corp (INCY) Q3 2020 Earnings Call Transcript

Incyte Corporation (INCY) Q3 2020 Earnings Conference Call November 5, 2020 08:00 AM ET Company Participants Mike Booth - Head of Investor Relations Hervé Hoppenot - Chairman, President & Chief Executive Officer Barry Flannelly - Executive Vice President, General Manager, US Steven S...

The following slide deck was published by Incyte Corporation in conjunction with their 2020 Q3 earnings call. For further details see: Incyte Corporation 2020 Q3 - Results - Earnings Call Presentation

Incyte (INCY): Q3 Non-GAAP EPS of $0.23 misses by $0.53; GAAP EPS of -$0.07 misses by $0.57.Revenue of $620.64M (+12.5% Y/Y) misses by $1.84M.Shares +0.22% PM.Press Release For further details see: Incyte EPS misses by $0.53, misses on revenue

Total product and royalty revenues of $621 million (+16% vs Q3 2019) for the quarter ended September 30, 2020; Jakafi ® (ruxolitinib) revenues of $488 million in Q3 2020 (+13% vs Q3 2019); Incyte tightens full year 2020 Jakafi revenue guidance to a range of $1.910 to $1...

- Numerous abstracts, including 7 oral presentations, highlighting data for ruxolitinib, parsaclisib, tafasitamab and ponatinib to be exhibited Incyte (Nasdaq: INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at th...